Recently, the ANDA product that independently developed by Yaopharma Co., Ltd. named Duloxetine delayed-release capsules (20mg, 30mg, 60mg), was approved by the US FDA. This is the first modified release preparation of Yaopharma Co., Ltd. that enter the US market.

Duloxetine delayed-release capsules are a serotonin and norepinephrine reuptake inhibitor (SNRI) indicated for Major Depressive Disorder (MDD), Generalized Anxiety Disorder (GAD), Diabetic Peripheral Neuropathic Pain (DPNP) and Chronic Musculoskeletal Pain. With its better safety, well tolerability, quick and effective Efficacy, lower side effects, it has been widely accepted and applied in clinical practice.